A sign on the entrance to a pharmacy reads “Covid-19 Vaccine Not Yet Available” in Burbank, California on Nov. 23, 2020.
Robyn Beck | AFP | Getty Images
SINGAPORE — With several Covid-19 vaccine candidates showing promising trial outcomes, investors and analysts have turned increasingly optimistic that the pandemic could soon come to an end.
But an analysis by Citi Research showed that “herd immunity” may not start to form until late-2021. Herd immunity occurs when enough people in a population develop protection against a disease, and it can no longer spread easily within the community.
The bank said in a Monday report that developed economies, many of which have secured vaccine pre-orders, will first experience the economic benefits of herd immunity.
Overall, the bank predicts that Covid-19 vaccination could raise global GDP growth by 0.7 percentage points in 2021, and 3 percentage points in 2022 as economic activity returns to normal.
The Citi report followed recent news by several pharmaceutical companies announcing that late-stage trials of their Covid-19 vaccines have shown encouraging results. Among vaccine frontrunners are candidates jointly developed by Pfizer and BioNTech; AstraZeneca and the University of Oxford; as well as one by Moderna.
Citi’s analysis assumed that those three vaccine candidates would receive emergency approvals between next month and January 2021 — which would allow the pharmaceutical companies to produce and distribute their vaccines.
According to Citi, developed markets have collectively secured 85% of total bilateral pre-orders of Covid-19 vaccines. Countries such as the U.S., U.K., Japan, Canada, Australia and those in the European Union have ordered supplies that exceed their populations, the analysts added.
That means major developed economies could start wider distribution of the vaccines in the second or third quarter next year, and form herd immunity by the final three months of 2021, they explained.
“Most people, who seek vaccination, may be vaccinated at least by the end of 2021,” said the analysts.
Normalizing economic activity is projected to raise growth in developed markets by 1.2 percentage points in 2021 and 3.9 percentage points in 2022, said Citi.
In comparison, emerging markets could see growth increase by 0.1 percentage points in 2021 and by 2 percentage points in 2022, projected the bank.
The smaller economic benefits in emerging markets are partly because some countries, especially those in Asia such as China, have contained the virus and allowed most activity to resume, Citi explained. In addition, vaccine distribution may take a longer time to reach emerging economies, with lower-income countries potentially having to wait until end-2022 or even later, the bank added.
Emerging markets may have to rely on the Covax facility for vaccine supply, Citi analysts said, referring to the United Nations’ program that will subsidize rollouts of Covid-19 vaccines to low-income countries.
Citi said there are uncertainties that could alter the timing of its forecasts for when herd immunity will be reached.
Those factors include:
- Efficacy of vaccines and Covid-19 reproduction rate, which refers to the number of people that an infected individual goes on to infect.
- The speed at which mass production of vaccines can be ramped up.
- People’s acceptance to a vaccine.
The bank, citing a survey by Ipsos and the World Economic Forum, pointed out that vaccine acceptance appeared to have fallen in recent months. The survey conducted in October found that 73% of respondents across 15 economies intend to get vaccinated — 4 percentage points fewer than the same survey done three months earlier.
“In general, vaccine coverage should reach at least 70% to form some herd immunity,” said Citi.
“However, vaccine acceptance rates of 54%-59% in France, Hungary, Poland and Russia suggest potential delays in the timing of herd immunity by vaccination in some countries.”